RecruitingPhase 2Phase 3NCT06113640

Montelukast in Parkinson Disease

Clinical Study to Investigate the Possible Efficacy and Safety of Montleukast in Parkinson Disease

Sponsor

Mostafa Bahaa

Enrollment

60 participants

Start Date

Nov 5, 2023

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease

Summary

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (AD). Clinical manifestations of PD can vary, but a formal diagnosis relies on the presence of bradykinesia with rigidity and/or rest tremor according to Movement Disorder Society (MDS) criteria for PD. Non-motor symptoms, such as hyposmia, constipation, depression, and rapid eye movement (REM) sleep behavior disorder, are common and can in many cases manifest before classical motor symptoms. In later years, more emphasis has been put on non-motor symptoms, especially in the early stages of PD and which is evident in the proposed prodromal PD criterion by MDS.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether montelukast — a medication commonly used for asthma and allergies — can help slow the progression of Parkinson's disease by reducing inflammation in the brain. **You may be eligible if:** - You are 18 or older (men and women welcome) - You have been diagnosed with Parkinson's disease - You are currently taking levodopa (a standard Parkinson's medication) - You have a negative pregnancy test (if applicable) and are using effective contraception **You may NOT be eligible if:** - Your Parkinson's is caused by another condition (secondary parkinsonism) - You currently take anti-inflammatory drugs - You have an atypical Parkinson's syndrome - You have had previous brain surgery for Parkinson's - You are pregnant or breastfeeding - You have active cancer, alcohol or drug addiction, or a known allergy to the study medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGlevodopa-carbidopa

Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease

DRUGMontelukast

Montelukast and other CysLT1 antagonists are currently used as an adjuvant therapy for children and adults suffering from asthma. Other indications have been proposed and most evidence exists for the use of montelukast to treat allergic rhinitis, but its use in other inflammatory conditions, such as atherosclerosis and chronic obstructive pulmonary disease, have also been suggested.